Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 18 Aug 2022
PHARMAC makes cancer treatment available to more people
18 August 2022 - PHARMAC has confirmed today they are widening access from 1 September 2022 to a targeted cancer treatment, ...
Posted by Michael Wonder on 17 Aug 2022
Early phase oncology trials: why so many designs?
12 August 2022 - The past 30 years have seen a considerable effort on the part of statisticians to improve the ...
Posted by Michael Wonder on 17 Aug 2022
IQWiG annual report for 2021 is available
17 August 2022 - The IQWiG has published its 2021 annual report today. ...
Posted by Michael Wonder on 17 Aug 2022
bluebird bio announces U.S. commercial infrastructure to enable patient access to Zynteglo, the first and only FDA approved gene therapy for people with beta thalassaemia who require regular red blood cell transfusions
17 August 2022 - Innovative outcomes-based contract offering includes single upfront payment and up to 80% risk-sharing. ...
Posted by Michael Wonder on 17 Aug 2022
Accelerated approval of cancer drugs: no economic reward for drug makers that conduct confirmatory trials
17 August 2022 - The FDA uses expedited approval of drugs to speed the development and assessment of drugs that address ...
Posted by Michael Wonder on 17 Aug 2022
FDA approves first cell based gene therapy to treat adult and paediatric patients with beta thalassaemia who require regular blood transfusions
17 August 2022 - Today, the US FDA approved Zynteglo (betibeglogene autotemcel), the first cell-based gene therapy for the treatment of ...
Posted by Michael Wonder on 17 Aug 2022
Fears for patient safety with hundreds of medicines in short supply
17 August 2022 - Doctors and pharmacists are warning there could be serious consequences for patients if the shortage of hundreds ...
Posted by Michael Wonder on 17 Aug 2022
Samsung Bioepis and Organon announce FDA approval of citrate free high concentration Humira biosimilar Hadlima (adalimumab-bwwd)
17 August 2022 - Samsung Bioepis and Organon today announced the U.S. FDA has approved the citrate free, high concentration (100 ...
Posted by Michael Wonder on 17 Aug 2022
COVID vaccine rollout too slow, poorly planned, audit finds
17 August 2022 - An audit of Australia’s coronavirus vaccination rollout has criticised the slow speed at which early doses ...
Posted by Michael Wonder on 17 Aug 2022
Akorn announces FDA has approved generic cetrorelix acetate
16 August 2022 - Akorn announces that it received FDA approval for a generic version of cetrorelix acetate 250 mcg ...
Posted by Michael Wonder on 17 Aug 2022
US FDA accepts new drug application for GSK’s momelotinib for the treatment of myelofibrosis
17 February 2022 - Regulatory submission included data from the pivotal MOMENTUM Phase 3 clinical trial that met all primary ...
Posted by Michael Wonder on 17 Aug 2022
UK will not buy Evusheld owing to “insufficient data” on protection, Government says
15 August 2022 - The UK Government has said that it will not procure the COVID-19 drug Evusheld—a combination of ...
Posted by Michael Wonder on 17 Aug 2022
PHARMAC estimates Trikafta could give people with CF another 27 years
17 August 2022 - PHARMAC has today published the record of advice from the May PTAC meeting to again consider ...
Posted by Michael Wonder on 17 Aug 2022
Restart of the National Medicines Policy review – further consultation on a revised draft
17 August 2022 - The Department of Health and Aged Care is inviting stakeholders to provide feedback on a revised ...
Posted by Michael Wonder on 16 Aug 2022
Sales from controversial drug discount program rose to $44 billion last year
15 August 2022 - Prescription medicines purchased in the US under a controversial government discount program amounted to $44 billion ...